Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 109

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 109
---

certain conditions. We are required to file each licensed patent application at least in the United States, Europe and Japan. We are also
required to take action, in reasonable commercial circumstances and after consultation with patent counsel, in the prosecution, prevention
or termination of any infringement of patents licensed under the agreement. We are responsible for the expenses of any patent infringement
suit that we bring, including the expenses incurred by Yissum in connection with such suits. We are entitled to reimbursement from any
awards or settlements recovered in such suit or in the settlement thereof for all costs and expenses involved in the prosecution of any
such suit. If we elect not to pursue any action in connection with infringement and Yissum in good faith disagrees with us that it is
in the mutual best interest of both parties not to pursue any such action, then, at our election, we may either allow Yissum to pursue
such actions, at Yissum’s expense, or pay Yissum the royalties that Yissum would otherwise receive from us attributable to lost
sales resulting from such alleged infringement

Research and Option Agreement with Yissum for the ARB Blockers

On October 25, 2023, we entered into Research
and Option Agreement with Yissum with respect to the nanoparticles-based formulation of angiotensin receptor blockers (ARB) for intravenous
administration. Under the agreement, we shall provide funding for research and development studies to be performed by researchers at
Hebrew University related to the formulation, preparation and characterization of nanoparticles-based formulation of angiotensin receptor
blockers (ARB) for intravenous administration. In consideration for the research services, we agreed to pay research service fees of
$150,000, in periodic payments subject to completing specified milestones. All data generated from the provision of the services, including
any reports, which are specifically required and contemplated under such agreement, shall be owned by us upon full payment of the research
services fees. If a patentable invention arises from the research, we shall be responsible for funding the costs of the patent application.
Each party will be entitled to terminate the agreement in the event of a breach by the other party of its obligations under the agreement,
including, but not limited to, any payment failure, which is not remedied by the breaching party within 30 days of receipt of written
notice from the non-breaching party.

The Company has the exclusive right within
90 days from receipt of the final scientific report to exercise the option